Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | LAP3 | P28838 | 2/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339158 | 0.98 | FDPS (0.59) | FDPSFOLH1LAP3GPR84FFAR1 | |
| SCHEMBL3470937 | 0.98 | FDPS (0.59) | FDPSFOLH1LAP3GPR84FFAR1 | |
| SCHEMBL3472188 | 0.98 | FDPS (0.59) | FDPSFOLH1LAP3GPR84FFAR1 | |
| SCHEMBL30595172 | 0.98 | FDPS (0.59) | FDPSFOLH1LAP3GPR84FFAR1 | |
| SCHEMBL5575815 | 0.98 | FDPS (0.59) | FDPSFOLH1LAP3GPR84FFAR1 | |
| SCHEMBL9487038 | 0.98 | FDPS (0.59) | FDPSFOLH1LAP3GPR84FFAR1 | |
| SCHEMBL3377184 | 0.98 | FDPS (0.59) | FDPSFOLH1LAP3GPR84FFAR1 | |
| SCHEMBL9841018 | 0.98 | FDPS (0.59) | FDPSFOLH1LAP3GPR84FFAR1 | |
| SCHEMBL2023917 | 0.98 | FDPS (0.59) | FDPSFOLH1LAP3GPR84FFAR1 | |
| Butane SCHEMBL2906335 | 0.96 | FDPS (0.57) | FDPSFOLH1LAP3GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0544345-B1 | Corrosion and/or scale inhibition | FMC CORP UK LTD (GB) | 1996-08-14 | — | — | EP | claimed |
| US-5294371-A | Hydroxyphosphonoacetic acid derivatives | FMC CORPORATION (US) | 1994-03-15 | — | — | US | claimed |
| EP-0544345-A1 | Corrosion and/or scale inhibition | FMC CORPORATION (UK) LIMITED (GB) | 1993-06-02 | — | — | EP | claimed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| WO-2017184428-A1 | CORROSION INHIBITING FORMULATION FOR DRILLING FLUID BRINES | Lubrizol Oilfield Solutions, Inc. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-8101635-B2 | Use of glutamate antagonists which is a NMDA receptor antagonist ( ifenprodil, memantine) to reduce or control retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy ( vision defect ) | ALLERGAN, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7264951-B1 | Enhanced production of taxol and taxanes by cell cultures of Taxus species | PHYTON, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7230032-B2 | Calcium blockers to treat proliferative vitreoretinopathy | ALLERGAN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-0994709-A4 | CALCIUM BLOCKERS TO TREAT PROLIFERATIVE VITREORETINOPATHY | ALLERGAN INC (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-0786018-A1 | CORROSION INHIBITING COMPOSITIONS | FMC Corporation (UK) Limited (GB) | 1997-07-30 | — | — | EP | disclosed |
| EP-0544345-B1 | Corrosion and/or scale inhibition | FMC CORP UK LTD (GB) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996011291-A1 | CORROSION INHIBITING COMPOSITIONS | FMC CORPORATION (UK) LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| US-5294371-A | Hydroxyphosphonoacetic acid derivatives | FMC CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0544345-A1 | Corrosion and/or scale inhibition | FMC CORPORATION (UK) LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| EP-0242709-A2 | Antagonists of specific excitatory amino acid neurotransmitter receptors | NOVA PHARMACEUTICAL CORPORATION (US) | 1987-10-28 | — | — | EP | disclosed |
| WO-1987006131-A1 | ANTAGONISTS OF SPECIFIC EXCITATORY AMINO ACID NEUROTRANSMITTER RECEPTORS | RZESZOTARSKI JANUSZ WACLAW (US) | 1987-10-22 | — | — | WO | disclosed |
| US-4657899-A | ANALGESICS, COGNITION ACTIVATORS | NOVA PHARMACEUTICAL CORPORATION (US) | 1987-04-14 | — | — | US | disclosed |
| US-4483853-A | ANTICONVULSANTS | COLLINS JAMES F | 1984-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | FDPS 1875/4885FOLH1 757/4885LAP3 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.